NCT03965845 - A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 25, 2019

Primary Completion Date

September 24, 2021

Study Completion Date

September 24, 2021

Conditions

Solid TumorsNSCLCCRCKRAS Gene Mutation

Interventions

DRUG

Telaglenestat (CB-839)

Teleglenastat is an oral tablet administered twice daily with food at the assigned dose level. Dose is taken with palbociclib each day in 28-day cycles.

DRUG

Palbociclib Oral Capsule or Tablet [Ibrance]

Palbociclib (Ibrance) is an oral capsule or tablet administered once daily with food on Days 1-21 of every 28-day cycle in combination with telaglenestat. Days 22-28 of every cycle, palbociclib is not taken.

Trial Locations (10)

30322

Emory, Winship Cancer Institute, Atlanta

37203

Sarah Cannon Research Institute- Tennessee Oncology, Nashville

52242

University of Iowa Hospitals and Clinics, Iowa City

53792

University of Wisconsin Clinical Science Center, Madison

55101

Regions Cancer care Center, Saint Paul

60611

Northwestern University Feinberg School of Medicine, Chicago

60612

Rush University Medical Center, Chicago

77030

MD Anderson, Houston

78229

South Texas Accelerated Research Therapeutic, LLC, San Antonio

90095

UCLA Hematology/Oncology, Santa Monica